Skip to content

Cancer Risk Associated with Anti-diabetic Medication - Valid Evaluation of Research questions by the Diabetes Institutes Collaborative Team

Cancer Risk Associated with Anti-diabetic Medication - Valid Evaluation of Research questions by the Diabetes Institutes Collaborative Team - C-VERDICT

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000010618
Enrollment
1140
Registered
2013-05-06
Start date
2013-05-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Cancer

Interventions

None listed

Sponsors

National Center fo Global Health and Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Those who meet all the following criteria. Only solid cancers are included;carcinoma in situ is included;precancerous lesion is not included. The diagnosis of cancer is according to physician's clinical judgment documented in medical records. 1) Type 2 diabetes mellitus that was diagosed in reference to the criteria by the Japan Diabetes Society, physician's judgement or self-report. 2) Japanese subjects 18 years of age or older. 3) Using any anti-diabetic agent at the time of cancer diagnosis (those only using insulin can also be registered). 4) Duration of diabetes 3 years or longer at the time of cancer diagnosis (if a subject had visited the clinic for shorter than 3 years, the medications given at the prior clinic need to be documented). 5) (cases) Those who have been visiting clinics and have been diagnosed of having cancer since January 2010. 6) (controls) Those who have been visiting clinics and have not been diagnosed of having cancer since January 2010.

Exclusion criteria

Exclusion criteria: Those who meet any of the following criteria. 1) (cases) Cancer diagnosis within 3 years of the initiation of diabetes treatment. 2) Pregnancy during the past 3 years of cancer diagnosis. 3) Taking only diet therapy at the time of cancer diagnosis 4) Ever treated overseas during the past 3 years of cancer diagnosis.

Design outcomes

Primary

MeasureTime frame
Odds ratio of cancer incidence per oral hypoglycemic agent

Countries

Japan

Contacts

Public ContactHiroshi Noto

National Center fo Global Health and Medicine Dept of Diabetes and Metabolic Medicine

noto-tky@umin.net03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026